ProCE Banner Activity


New Options for Schizophrenia Management: Current and Emerging Treatment Options

Medical Minute

In the final Medical Minute of this 3-part series, Dr Leslie Citrome provides valuable information on available and emerging antipsychotics for treatment of schizophrenia. He discusses efficacy and tolerability of various formulations, including the common patient concern of medication-induced weight gain. Also included are tables comparing the qualities of long-acting injectable antipsychotics, real-world evidence for patient and caregiver attitudes towards long-acting injectables, and information on the utility of transdermal patches in patients with schizophrenia.

Physician Assistants: maximum of 0.50 hours of AAPA Category 1 CME credits Registered Nurses: 0.50 Nursing contact hours, includes 0.50 hour of pharmacology credit

Released: July 07, 2022

Expiration: July 06, 2023

No longer available for credit.



Leslie Citrome

Leslie Citrome, MD, MPH

Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Amber Hoberg

Amber Hoberg, PMHNP

Nurse Practitioner
MorningStar Family Medicine
Floresville, Texas


This activity is supported by educational grants from Alkermes, Inc. and Teva Pharmaceuticals.

Provided by

ProCE Banner


Alkermes, Inc.

Teva Pharmaceuticals

Target Audience

NPs and PAs

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Outline efficacy and safety data of recently approved and emerging antipsychotics for the treatment of schizophrenia


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Leslie Citrome, MD, MPH, consultant: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent, Cerevel, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, INmune Bio, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, MedavanteProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Praxis, Relmada, Reviva, Sage, Sunovion, Supernus, Takeda, Teva; speaker: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, Teva; ownership interest: Bristol-Myers Squibb, Johnson & Johnson, Lilly, Merck, Pfizer, Reviva.

Amber Hoberg, PMHNP, consultant/advisor/speaker: Acadia, Avanir, BioXcel, Intracellular Therapies, Neurocrine, and Teva.

Gabrielle Giacona individual publicly traded stocks/stock options: AstraZeneca, Moderna, and Teva.

Amanda Zimmerman, PA-C, research support/fees for non-CME/CE services: BioDelivery Sciences International.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Gabrielle Giacona and Amanda Zimmerman, PA-C as noted above.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the post-test and evaluation form

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 100%.

The estimated time to complete this activity is 0.25 hours.

Release date: July 7, 2022
Expiration date: July 6, 2023


Medical Minute


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 0.25, which includes 0.25 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until July 6, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Amanda Zimmerman, PA-C, West Forsyth Pain Management, Winston-Salem, North Carolina

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.